Assembly Biosciences (NASDAQ:ASMB) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $15.65 and traded as high as $17.68. Assembly Biosciences shares last traded at $17.37, with a volume of 23,726 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ASMB. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th. Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $2.00 to $35.00 in a research report on Friday, September 20th.

Assembly Biosciences Price Performance

The firm has a 50-day moving average of $16.03 and a 200 day moving average of $15.67.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton purchased 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the purchase, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in ASMB. JPMorgan Chase & Co. lifted its holdings in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 131.0% in the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 7,690 shares during the last quarter. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 3,635 shares during the last quarter. Renaissance Technologies LLC grew its position in Assembly Biosciences by 39.2% during the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Assembly Biosciences during the 2nd quarter worth approximately $6,421,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.